PYY 3-36 crosses the blood-brain-barrier (Nonaka, Shioda et al
However, pharmaceutical companies have neglected to highlight the numerous health risks associated with Ozempic and Wegovy
Dosing adjustments and special considerations Holding or reducing dose When to hold at current dose: Moderate-to-severe GI symptoms Symptoms that haven't resolved after 3-4 weeks Any concerning side effects When to reduce dose: Symptoms intolerable at current level Significant weight loss plateau doesn't require maximum dose Maintenance phase after reaching goals How to hold: Stay at current dose for an additional 2-4 weeks Then attempt escalation again If symptoms recur, may need to maintain at lower dose Missed dose protocol If you miss a dose: Take it as soon as you remember if within 4-5 days If more than 5 days, skip and resume normal schedule Never double dose to make up for missed injection If you frequently miss doses: Set weekly reminders Choose a consistent day (many choose Sunday) Consider adjusting day if schedule conflicts Population considerations For those with kidney impairment: Limited data available Slower titration may be warranted More frequent monitoring recommended Discuss with provider before starting For those with liver impairment: Retatrutide is hepatically metabolized Caution in moderate-to-severe liver disease May need dose adjustments Requires provider guidance For women: Similar dosing to men in trials May have stronger appetite suppression effects Some may need slower titration Contraception recommended during treatment For older adults: May need slower titration Increased monitoring for dehydration Start at lowest dose More frequent check-ins Comparing retatrutide dosing to other medications Retatrutide vs
It also forms a protective barrier on the skin, preventing moisture loss and improving the overall texture and appearance of the skin
She told me a major concern with compounded drugs is the lack of reliability around dose, formulation and source. She also explained that these unapproved products do not come with warning labels that advise their providers of the risks of taking the drug. This raises questions over true informed consent for patients
Journal of Hazardous Materials, 270 , 153159
